Lymphoma, B-Cell News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Immune cell therapy results are 'landmark moment' in lymphoma treatment - Cancer Research UK



Cancer Research UK
 
Immune cell therapy results are 'landmark moment' in lymphoma treatment 
Cancer Research UK
Four in 10 patients with aggressive lymphoma were cancer-free 15 months after treatment with engineered immune cells, according to new US clinical trial results. The study involved 108 patients with large B cell lymphoma who didn't respond to standard ...
Yescarta Benefits 42% of Patients a Year After Infusion Managed Care magazine
Living Drugs For Cancer - ASH Update Nasdaq
New CAR-T Cancer Studies Aim to Treat Those With No Other Options Futurism
AJMC.com Managed Markets Network  -Madison.com  -Pharmacy Today, American Pharmacists Association, pharmacist.com 
all 16 news articles » 


ASH: Anti-CD19 CAR T-cell Tx beneficial in B-cell lymphomas - Medical Xpress



Medical Xpress
 
ASH: Anti-CD19 CAR T-cell Tx beneficial in B-cell lymphomas 
Medical Xpress
Sattva S. Neelapu, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma with refractory ...
Global CAR T therapy trial shows high rates of durable remission for non-Hodgkin's lymphoma Science Daily
CAR T-cell therapies drive outcomes in lymphoma, myeloma EurekAlert (press release)
Novel immunotherapy brings new hope for cancer patients Daily Pioneer
Newswise (press release)  -TheHealthSite 
all 29 news articles » 


Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple ... - Markets Insider



Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple ... 
Markets Insider
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2017 /PRNewswire/ -- Two studies presented yesterday at the American Society of Hematology's annual meeting in Atlanta showed frequent expression of CD74, a cell-surface protein in hematologic B-cell malignancies ...

and more » 


Cemiplimab Monotherapy Induces 50% ORR in Hodgkin Lymphoma - Targeted Oncology



Cemiplimab Monotherapy Induces 50% ORR in Hodgkin Lymphoma 
Targeted Oncology
Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with Hodgkin lymphoma (HL) in a phase I study of patients with B-lymphoid malignancies; among patients with B-cell non-Hodgkin lymphoma (B-NHL) treated with ...

 


Autoimmune conditions, infections common among diffuse large B ... - Healio



Autoimmune conditions, infections common among diffuse large B ... 
Healio
ATLANTA ? Adults with diffuse large B-cell lymphoma had increased risk for developing autoimmune and infectious diseases within 10 years from diagnosis compared with breast and prostate cancer survivors, according to findings from a population-based ...

and more » 


Pembrolizumab Receives FDA's Priority Review in PMBCL - Targeted Oncology



Targeted Oncology
 
Pembrolizumab Receives FDA's Priority Review in PMBCL 
Targeted Oncology
Pembrolizumab (Keytruda) has received a priority review from the FDA for a supplemental biologics license application (sBLA) for the treatment of adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL ...
Elderly Patients Significantly Underrepresented in Hematology ... Curetoday.com

all 3 news articles » 


Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma - Nasdaq



Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma 
Nasdaq
MerckMRK announced that the FDA has granted priority review to its supplemental biologics license application (sBLA) looking for label expansion of its marketed drug, Keytruda (pembrolizumab), for a rare lymphoma indication. The sNDA is looking to ...

and more » 


Keytruda Gets Priority Review for Lymphoma Subset - Cure Today - Curetoday.com



Curetoday.com
 
Keytruda Gets Priority Review for Lymphoma Subset - Cure Today 
Curetoday.com
Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat adult and pediatric patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).
FDA accepts Merck's marketing application for Keytruda for type of ... Seeking Alpha

all 4 news articles » 


Phase 2 data for Roche's lymphoma ADC doesn't disappoint ... - FierceBiotech



FierceBiotech
 
Phase 2 data for Roche's lymphoma ADC doesn't disappoint ... 
FierceBiotech
With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche's antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented at ASH 2017 suggests that ...
ADC Therapeutics' New Drug Offers Hope to Hard-to-Treat Cancer ... Labiotech.eu (blog)

all 2 news articles » 


Treatment Strategies in Primary Mediastinal B-Cell Lymphoma - Cancer Network



Cancer Network
 
Treatment Strategies in Primary Mediastinal B-Cell Lymphoma 
Cancer Network
As part of our coverage of the American Society of Hematology (ASH) Annual Meeting & Exposition held December 9?12 in Atlanta, we are speaking with Kieron Dunleavy, MD, about the latest strategies to treat primary mediastinal B-cell lymphoma (PMBCL ...